Imperial College London


Faculty of MedicineSchool of Public Health

Head of Operations



+44 (0)20 7594 Website




Stadium HouseWhite City Campus





Dr Justine Reise is the Head of Operations for the UKCRC registered Imperial Clinical Trials Unit (ICTU) in the School of Public Health within the Faculty of Medicine at Imperial College.

A graduate in Biochemistry from University College London, with a PhD in Pharmacology / Analytical Chemistry from Imperial College London, Justine has over 20 years experience of conducting clinical research within academia and aligned with the National Health Service, across multiple areas of  interest including vascular surgery, oncology and patient preference / involvement.

At ICTU, she leads a multi-disciplinary team of clinical research staff responsible for the day to day conduct of the clinical trials and studies on the unit portfolio, ensuring  activities are undertaken to the highest scientific and regulatory standards.




Stebbing J, Payne R, Reise J, et al., 2013, The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study, Plos One, Vol:8, ISSN:1932-6203

Coombes RC, Tat T, Miller ML, et al., 2013, An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study), Annals of Oncology, Vol:24, ISSN:0923-7534, Pages:924-930

Bliss JM, Kilburn LS, Coleman RE, et al., 2012, Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study, Journal of Clinical Oncology, Vol:30, ISSN:0732-183X, Pages:709-717

Coombes RC, Bliss JM, Espie M, et al., 2011, Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer, Journal of Clinical Oncology, Vol:29, ISSN:0732-183X, Pages:3247-3254

Coombes RC, Reise JA, Lau M, et al., 2011, An open-label positron emission tomography (PET) study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing (HER2+) advanced or metastatic breast cancer (MBC)., Journal of Clinical Oncology, Vol:29, ISSN:0732-183X

More Publications